Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21672350 | 0.81 | SSTR4 (0.36) | SSTR4GRM5MAPK1MAPTMC4R | |
| SCHEMBL11318719 | 0.77 | SSTR4 (0.36) | SSTR4GRM5MAPK1MAPT | |
| SCHEMBL11317113 | 0.77 | GRM5 (0.36) | SSTR4GRM5MAPK1MAPTMC4R | |
| SCHEMBL22494147 | 0.77 | SSTR4 (0.34) | SSTR4GRM5MAPK1MC4R | |
| SCHEMBL14048241 | 0.75 | MAPT (0.35) | SSTR4MAPTMC4R | |
| SCHEMBL20434829 | 0.74 | SSTR4 (0.50) | SSTR4GRM5MAPK1MAPT | |
| Bromide SCHEMBL11829058 | 0.73 | MC4R (0.32) | SSTR4GRM5MC4R | |
| SCHEMBL12857326 | 0.72 | SSTR4 (0.49) | SSTR4GRM5MAPK1MAPT | |
| SCHEMBL21941495 | 0.72 | SSTR4 (0.46) | SSTR4GRM5MAPK1 | |
| SCHEMBL9044124 | 0.72 | SSTR4 (0.32) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710975-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710975-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | SSTR4 1624/4885GRM5 499/4885MAPK1 2862/4885 |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | SSTR4 1624/4885GRM5 499/4885MAPK1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.